The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:
* Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population?
Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health.
Participants will:
* Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.
Emiratis residing in Abu Dhabi emirate
Aged 25-50 years
BMI 30-35 kg/m²
Thiqa cardholder
Aged under 25 years or over 50 years of age
BMI range under 30 kg/m2 and over 35 kg/m2
Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)
Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)
Parallel
Precision Lifestyle Medicine Program
BehavioralParticipants receive an 18-week precision lifestyle medicine intervention based on individual IFHAS screening results and cardiometabolic risk stratification. The program includes personalized lifestyle recommendations and multidisciplinary clinical support focused on improving cardiometabolic health. Participants are followed for 24 weeks, with assessments conducted at baseline and post-intervention.
Standard IFHAS Care
Other interventionParticipants receive standard IFHAS care without participation in the precision lifestyle medicine intervention. This group serves as a propensity score-matched comparison cohort.
Change in Body Mass Index (BMI)
Mean change in body mass index (BMI) from baseline to Week 24 following the precision lifestyle medicine intervention.
Change in Cardiometabolic Composite Response
Proportion of participants classified as cardiometabolic responders at Week 24, defined as achieving at least two of the following: ≥3% reduction in body weight, ≥5% reduction in ApoB (or LDL-C), ≥0.3% reduction in HbA1c (or ≥15% reduction in HOMA-IR), ≥3 mmHg reduction in systolic blood pressure, or ≥2 cm reduction in waist circumference.
High responder rate
Proportion of participants meeting at least three of the five cardiometabolic composite response criteria.
Change in body weight
Mean percent change in body weight from baseline.
Change in HbA1c
Mean change in HbA1c among participants with dysglycaemia.
Change in ApoB
Mean change in apolipoprotein B concentration.
Click on the lead sponsor to view all of their trials.
Institute for Healthier Living Abu Dhabi
Lead sponsor
Abu Dhabi Public Health Centre
Collaborator